Key facts
- This page summarizes RTW INVESTMENTS, LP's Form 4 filing for Milestone Pharmaceuticals Inc. (MIST).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 24 Mar 2023, 16:30.
RTW INVESTMENTS, LP - 22 Mar 2023 Form 4 Insider Report for Milestone Pharmaceuticals Inc. (MIST)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- MIST
- Reported as of
- 22 Mar 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Mar 2023, 16:30:34 UTC
- Prior SEC filing
- 30 Jan 2023
- Next SEC filing
- 05 May 2023
- Source filing
- View source filing
- Reporting owner signature
- RTW Investments, LP, By: /s/ Roderick Wong, Managing Partner
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
RTW INVESTMENTS, LP filed Form 4 for Milestone Pharmaceuticals Inc. (MIST) on 24 Mar 2023.
Change
- Previous filing in this sequence was filed on 30 Jan 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MIST
transaction
Common Shares, no par value ("Common Shares")
Other
- Transaction value
- Shares
- -1,059,000
- Change %
- -25%
- Price
- Shares after
- 3,256,102
- Date
- 22 Mar 2023
- Ownership
- See footnote
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
RTW INVESTMENTS, LP is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
The RTW Funds (as defined below) exchanged 1,059,000 Common Shares for 1,059,000 pre-funded warrants pursuant to an Exchange Agreement, dated as of March 22, 2023, by and among the Issuer and the RTW Funds. Each pre-funded warrant represents the right to acquire one Common Share for an exercise price of $0.001 per share. The pre-funded warrants are subject to a 9.99% beneficial ownership limitation and do not have an expiration date.
Footnote F2
This Form 4 is being filed by each of (i) RTW Investments, LP (the "Adviser") with respect to Common Shares held by certain investment funds managed by the Adviser (the "RTW Funds"), and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser.